

Listing of Claims

This Listing of Claims will replace all prior version and listings of claims in the Application.

1. (CURRENTLY AMENDED) A method of treating one or more cells undergoing uncontrolled growth comprising the step of:

contacting the one or more cells with an antibody to ralA binding protein1, wherein the ~~direct~~ contact is cytotoxic to the one or more cells in the absence of an additional agent and wherein the antibody blocks the function of the ralA binding protein1.

2. (ORIGINAL) The method of claim 1, wherein one or cells are selected from the group consisting of cancerous cells, NCI-H82, NCI-H182, NCI-1417, NCI-1618, NCI-H1395, NCI-H2347, HCC44 (adenocarcinoma), and NCI-H2126 (large cell), and combinations thereof.

3. (WITHDRAWN) The method of claim 1, wherein the antibody inhibits the transport activity of ralA binding protein1.

4. (ORIGINAL) The method of claim 1, wherein the antibody is added in combination with a drug to prevent the drug from leaving the cell.

5. (ORIGINAL) The method of claim 4, wherein the drug is used for chemotherapy.

6 (PREVIOUSLY PRESENTED) The method of claim 1, wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, ralA binding protein1 IgG raised against an effective portion of RLIP76.

7. (ORIGINAL) The method of claim 4, wherein the drug is at least selected from the group consisting of doxorubicin, actinomycin, actinomycin D, altretamine, asparaginase, bleomycin, busulphan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, , epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, herceptin, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitozantrone, oxaliplatin, procarbazine, rituxan, steroids, streptozocin, taxol, taxotere, tamozolamide, thioguanine, thiotepa, tomudex, topotecan, treosulfan, uracil-tegafur, vinblastine, vincristine, vindesine, vinorelbine, and effective combinations and analogs thereof.

8. (ORIGINAL) The method of claim 4, wherein addition of the drug to the antibody enhances the cytotoxicity of the drug.
9. (ORIGINAL) The method of claim 4, wherein antibody promotes apoptosis of the cell.
10. (ORIGINAL) The method of claim 1, wherein the antibody is added in combination with radiation therapy.
11. (ORIGINAL) The method of claim 10, wherein the antibody in combination with radiation therapy enhances effectiveness of the radiation therapy.
12. (WITHDRAWN) A pharmaceutical composition for the treatment of one or more cells undergoing uncontrolled growth comprising:
an antibody to RLIP76, wherein the antibody comprises all or an effective portion thereof that effectively reduces the transport activity of RLIP76; and
a pharmaceutically effective carrier.
13. (WITHDRAWN) The pharmaceutical composition of claim 11, wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, RLIP76 IgG raised against an effective portion of RLIP76.
14. (WITHDRAWN) The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is used in combination with a drug.
15. (WITHDRAWN) The pharmaceutical composition of claim 11, wherein addition of the drug to the pharmaceutical composition enhances the cytotoxicity of the drug.
16. (WITHDRAWN) The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is used in combination with radiation therapy.
17. (WITHDRAWN) The pharmaceutical composition of claim 11, wherein radiation of the pharmaceutical composition enhances the effect of radiation treatment.
18. (WITHDRAWN) The pharmaceutical composition of claim 11, wherein the pharmaceutical composition promotes apoptosis of the cells.

19. (CURRENTLY AMENDED) A method of locating a cell undergoing uncontrolled growth comprising the step of:

contacting the one or more cells with an antibody to ralA binding protein1, wherein the antibody is connected to a tracer molecule and the tracer molecule is capable of identifying the location of the one or more cells ~~in the absence of an additional agent and wherein the antibody blocks the function of the ralA binding protein1.~~

20. (PREVIOUSLY PRESENTED) The method of claim 19, wherein the antibody is administered to mammal.